Telix Pharmaceuticals has been granted a permanent Healthcare Common Procedure Coding System (HCPCS) code from the U.S. Centers for Medicare and Medicaid Services (CMS) for its prostate cancer imaging kit Gozellix.
Gozellix was approved in March for PET imaging in men with prostate-specific membrane antigen (PSMA)-positive lesions and suspected metastasis who are candidates for initial definitive therapy and those with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
Effective October 1, CMS and commercial health insurers will recognize the HCPCS Level II code A9616 assigned for reimbursement of Gozellix, Telix said.
